{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:43:30Z","timestamp":1788241410421,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":127,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara University","doi-asserted-by":"publisher","award":["TTU-2022-2464"],"award-info":[{"award-number":["TTU-2022-2464"]}],"id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100514","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:09:07Z","timestamp":1746792547000},"page":"100514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9034-2894","authenticated-orcid":false,"given":"Ugur","family":"Calis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Aydogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guldane Cengiz","family":"Seval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Dalva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selami Kocak","family":"Toprak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2025.100514_bib0001","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2025.100514_bib0002","article-title":"Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis","volume":"12","author":"Zhao","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lrr.2025.100514_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","article-title":"Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia","volume":"11","author":"Yang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.lrr.2025.100514_bib0004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lrr.2025.100514_bib0005","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2278229","article-title":"Higher PD-1\/Tim-3 expression on IFN-gamma+ T cells is associated with poor prognosis in patients with acute myeloid leukemia","volume":"24","author":"Huang","year":"2023","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.lrr.2025.100514_bib0006","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100514_bib0007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jha2.10","article-title":"PD1 expression on bone marrow T-cells in newly diagnosed Egyptian AML patients: correlation with hematological parameters, aberrant antigens expression, and response to induction therapy","volume":"1","author":"Bassiouny","year":"2020","journal-title":"EJHaem"},{"key":"10.1016\/j.lrr.2025.100514_bib0008","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-018-0069-4","article-title":"Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients","volume":"8","author":"Jia","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.lrr.2025.100514_bib0009","first-page":"106","article-title":"Expression of programmed death ligand-1 (PDL-1) in acute myeloid leukemia patients and its relation to post induction response","volume":"2","author":"La Abdel Hafeez","year":"2021","journal-title":"SECI Oncol."},{"key":"10.1016\/j.lrr.2025.100514_bib0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/ejh.ejh_27_18","article-title":"Prognostic significance of programmed death ligand 1 expression in adult patients with De-novo acute myeloid leukemia","volume":"43","author":"Mostafa","year":"2018","journal-title":"Egypt. J. Haematol."},{"key":"10.1016\/j.lrr.2025.100514_bib0011","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12288-021-01473-2","article-title":"Programmed cell death ligand 1 expression level and prognostic significance in acute myeloid leukemia","volume":"38","author":"Geduk","year":"2022","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.lrr.2025.100514_bib0012","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.lrr.2025.100514_bib0013","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.3390\/ijms20112823","article-title":"High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations","volume":"20","author":"Brodsk\u00e1","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lrr.2025.100514_bib0014","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.15040","article-title":"Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML","volume":"183","author":"Zajac","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lrr.2025.100514_bib0015","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 Mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100514_bib0016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10428199509051710","article-title":"CD7 Expression in acute myeloid leukemia","volume":"17","author":"Del Poeta","year":"1995","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lrr.2025.100514_bib0017","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/bjh.19446","article-title":"Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression","volume":"204","author":"Jen","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lrr.2025.100514_bib0018","article-title":"Targeted CD7 CAR T-cells for treatment of T-lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lrr.2025.100514_bib0019","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/cam4.2007","article-title":"CD9 in acute myeloid leukemia: prognostic role and usefulness to target leukemic stem cells","volume":"8","author":"Touzet","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.lrr.2025.100514_bib0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13287-021-02155-6","article-title":"CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia","volume":"12","author":"Liu","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.lrr.2025.100514_bib0021","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.blre.2017.03.004","article-title":"The bone marrow microenvironment - home of the leukemic blasts","volume":"31","author":"Shafat","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.lrr.2025.100514_bib0022","doi-asserted-by":"crossref","first-page":"463","DOI":"10.21147\/j.issn.1000-9604.2017.05.11","article-title":"Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia","volume":"29","author":"Tan","year":"2017","journal-title":"Chin. J. Cancer Res."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T17:15:32Z","timestamp":1750180532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":22,"alternative-id":["S2213048925000160"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100514","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100514"}}